Dexcom Inc（DXCM）財務資料DXCMDexcom Inc

Dexcom Inc (DXCM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Distributor, accounting for 84.3% of total sales, equivalent to $1.10B. Another important revenue stream is Direct. Understanding this composition is critical for investors evaluating how DXCM navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Dexcom Inc maintains a gross margin of 63.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 24.33%, while the net margin is 19.04%. These profitability ratios, combined with a Return on Equity (ROE) of 38.49%, provide a clear picture of how effectively DXCM converts its operational activities into shareholder value.

In the context of the broader market, DXCM competes directly with industry leaders such as RMD and MTD. With a market capitalization of $32.47B, it holds a leading position in the sector. When comparing efficiency, DXCM's gross margin of 63.44% stands against RMD's 58.12% and MTD's 61.40%. Such benchmarking helps identify whether Dexcom Inc is trading at a premium or discount relative to its financial performance.

Dexcom has demonstrated strong financial performance with total revenue increasing from $1.11 billion in Q4 2024 to $1.31 billion in Q2 2026. The gross margin has remained robust, averaging around 63% in recent quarters, indicating effective cost management.